

# Statutory Approvals Committee - minutes

## Centre 0102 (Guys Hospital) – PGD application for Antithrombin III Deficiency OMIM #613118

Thursday, 29 September 2016

HFEA, Level 2, 10 Spring Gardens, London, SW1A 2BU

Committee members	David Archard (Chair) Rebekah Dundas (Deputy Chair) Margaret Gilmore Anne Lampe Ruth Wilde	
Members of the Executive	Ian Brown Trent Fisher	Head of Corporate Governance Secretary
External adviser	Jenny Carmichael	
Legal Adviser	Jane Williams	Mills & Reeve LLP
Observers	None	

### Declarations of interest:

- members of the committee declared that they had no conflicts of interest in relation to this item.

### The committee had before it:

- 8th edition of the HFEA Code of Practice
- standard licensing and approvals pack for committee members

### The following papers were considered by the committee:

- executive summary
- PGD application form
- redacted peer review
- Genetic Alliance opinion
- email from the Executive
- expert opinion

- Statutory Approvals Committee minutes, 24 June 2016

---

## 1. Consideration of application

- 1.1. The committee noted that an application in respect of Antithrombin III Deficiency OMIM #613118 was previously tabled at its June 2016 meeting.
- 1.2. The committee, at that time, felt it did not have enough information to be able to consider authorising the testing of embryos for this condition. The committee requested the following information.
  - an opinion of a haematologist to include information regarding the treatment options available and the associated risks and impact related to the treatment options
  - a breakdown of the proportions of thrombotic events by life threatening events, events causing serious long term problems and less serious events
- 1.3. The committee noted that an expert review has been submitted by the centre but concluded, after due consideration, that the review did not provide enough current information in relation to the two points mentioned above.

---

## 2. Decision


- 2.1. The committee agreed that it still did not have sufficient information to make an informed decision.
- 2.2. The committee requests that it is provided with:
  - an opinion of a haematologist to include information regarding the treatment options available and the associated risks and impact related to the treatment options; and
  - a breakdown of the proportions of thrombotic events by life threatening events, events causing serious long term problems and less serious events.

---

## 3. Chair's signature

- 3.1. I confirm this is a true and accurate record of the meeting.

### Signature



### Name

David Archard

### Date

13 October 2016